Mapouka Mexan MD, MPH 🇨🇫🇺🇸

Internal Medicine Resident at the University of Maryland Capital Region Health | Passionate about Gastroenterology & Hepatology

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

https://t.co/yJeBIBttE0

[Healio Gastroenterology @HealioGastro]

❌ NO significant difference in #MASH, #CardiovascularDisease or mortality between lean and non-lean patients with #MASLD.

Don’t be blinded by #obesity -- lean MASLD patients might be slipping under the radar 🫣

@MapoukaMexan @UMCapitalRegion #ACG2025
https://t.co/HFLVMvtQox

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

Happy to share our newly published retrospective cohort study, in which we examined national trends in chronic pancreatitis hospitalizations across the United States over time!@SarpB44
#GITweet @AmerGastroAssn @AmCollegeGastro
#Pancreatitis #Pancreas

[Sarpong Boateng, MD, MPH @SarpB44]

Thank you, @AAFG_2021
We need to incorporate value-based care in MASH therapeutics
@DDWMeeting @basilenjei
#medtwitter #gitwitter

[Nkengeh N. Tazinkeng (Davy), MD @NkengehNTD]

Grateful for the opportunity to collaborate with these GI powerhouses on such an important topic.

Now available online at https://t.co/NufloLBQd6

#GITwitter #MedTwitter

[Nkengeh N. Tazinkeng (Davy), MD @NkengehNTD]

Congratulations @MapoukaMexan on leading this project 👏🏾

✍️ MA of 10M+ pts
✍️ Non-lean (vs lean) MASLD patients have 📈 odds of fibrosis, steatosis, cirrhosis & HTN
✍️ Risk of MASH, CVD, & mortality similar in both groups

📌 Screenx should go beyond BMI alone

#GITwitter #MASLD

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

Happy to share our newly published paper in the World Journal of Gastroenterology.
Please take a look at our findings exploring the differences in liver and cardiovascular metabolic disease outcomes between lean and non-lean MASLD patients.
Thanks to all the co-authors for their valuable contributions! @NkengehNTD #GITwitter #MedTwitter

https://t.co/3avO6emz2j

[Sarpong Boateng, MD, MPH @SarpB44]

🚨 New publication

Can AI improve the cost-effectiveness of screening for advanced fibrosis in MASLD?
Our latest study shows AI risk stratification + elastography outperforms traditional FIB-4–based screening, delivering greater gains at favorable cost-effectiveness thresholds.

🔗https://t.co/lbqJFqHkBi
#MASLD #Hepatology #ArtificialIntelligence #HealthEconomics

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

@basilenjei @NkengehNTD @GIE_Journal @SamIgbinedion @FatimaElmus @KristieLiao_DO @AAFG_2021 Thank you so much!

[Tyler Berzin MD, FASGE @tberzin]

@NkengehNTD @GIE_Journal @SamIgbinedion @FatimaElmus @MapoukaMexan @KristieLiao_DO @AAFG_2021 👏👏👏👏

[Nkengeh N. Tazinkeng (Davy), MD @NkengehNTD]

Excited to share our newly published article in @GIE_Journal
https://t.co/R9zjzKuYMP

Very thankful for the amazing mentorship of @SamIgbinedion and our wonderful team.

#GITwitter #Medtwitter

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

Upfront Endoscopic Necrosectomy Versus Step-Up Endoscopic Approach for Walled-off Pancreatic Necrosis: A systematic review and meta-analysis - Gastrointestinal Endoscopy https://t.co/5X6FkA7uTe @GIE_Journal

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

Happy to share our latest published work in @GIE_Journal on Upfront Endoscopic Necrosectomy vs. Step-Up Endoscopic Approach for Walled-off Pancreatic Necrosis!
https://t.co/WCXDuklhSM

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

@NkengehNTD @virtualmedconf @SomayaAlbhaisi @POHER_NGO @AAFG_2021 @jlouissaint89 @BrennanSpiegel Congratulations!!

[Basile Njei, MD, MPH, PhD @basilenjei]

#LLM #Liver #MASLD #Fibrosis #GPT

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

Thank you @HealioGastro
@AmCollegeGastro
Screening, surveillance for MASLD needs to expand ‘beyond BMI’ https://t.co/neUp27WGKd

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

Please check out our newly published case report on Salmonella presenting beyond the gastrointestinal tract.

https://t.co/CRsCiJj2ZW

@AmCollegeGastro
#GITwitter

[Nkengeh N. Tazinkeng (Davy), MD @NkengehNTD]

Excited to have been part of #TLM2025.
Key highlight was the hospitality of everyone I met, esp my co-ELS friends

Grateful to my mentors @LewisRobertsMD & @AkwiAsombangMD for the massive support pre- & post my ELS award; and to @ndshah85 & @AASLDFoundation for this opportunity

[Healio Gastroenterology @HealioGastro]

📰 Just in from #ACG2025: Non-lean #MASLD patients face higher risk of fibrosis, steatosis & hypertension 🆚 their lean counterparts.

🗨️ “#Obesity shouldn’t be the sole criterion for MASLD screening,” says @MapoukaMexan @UMCapitalRegion.
https://t.co/HFLVMvtQox

[Mapouka Mexan MD, MPH 🇨🇫🇺🇸 @MapoukaMexan]

I am so grateful for giving my oral presentation #ACG2025 today! And here are some key take away points: lean patients with MASLD may have same outcomes risk level of MASH (former NASH), cardiovascular diseases and mortality compared to non-lean MASLD in large pooled estimates!
There is a need to develop risk stratification for lean MASLD patients.
Thank you so much @AmCollegeGastro @ACG_CTG @AAFG_2021 #GITwitter @HealioGastro and to the moderators and those who attended!